


Varespladib methyl

Cat. No.:	HY-17448
CAS No.:	172733-08-3
Molecular Formula:	C ₂₂ H ₂₂ N ₂ O ₅
Molecular Weight:	394.42
Target:	Phospholipase
Pathway:	Metabolic Enzyme/Protease
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (253.54 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	2.5354 mL	12.6768 mL	25.3537 mL
		5 mM	0.5071 mL	2.5354 mL	5.0707 mL
10 mM	0.2535 mL	1.2677 mL	2.5354 mL		
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (12.68 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (PLA2).
IC₅₀ & Target	phospholipase A2 (PLA2) ^[1]
In Vitro	<p>Varespladib methyl (LY333013) is an orally-administered methyl ester pro-drug that is metabolized to LY315920^[1]. Varespladib and its orally bioavailable prodrug, Varespladib methyl (methyl-Varespladib) shows high-level secretory PLA2 (sPLA2) inhibition at nanomolar and picomolar concentrations against 28 medically important snake venoms from six continents^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- JCI Insight. 2021 Sep 7;151911.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Bradley JD, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. *J Rheumatol.* 2005 Mar;32(3):417-23.
- [2]. Lewin M, et al. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. *Toxins (Basel).* 2016 Aug 25;8(9). pii: E248.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA